Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 751 - 775 of 14415 in total
Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical". . This low affinity to dopamine receptors results in fewer extrapyramidal side effects,...
Approved
Matched Description: … side effects, notably gastrointestinal hypomotility and orthostatic hypotension. ... [A185747] However, its promiscuity toward the muscarinic and adrenergic receptors can result in other ... Despite its effectiveness in treating both positive and negative symptoms of schizophrenia, clozapine …
Matched Categories: … Diazepines, Oxazepines, Thiazepines and Oxepines …
Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993.
Approved
Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down into mesalazine and sulfapyridine, 2 compounds that carry out the main pharmacological...
Approved
Matched Description: … Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal ... It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis ... L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down into [mesalazine] and
Matched Categories: … Alimentary Tract and Metabolism …
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by...
Approved
Matched Description: … It is a potent and selective inhibitor of JAK1 and JAK2,[A229698] which are tyrosine kinases involved ... By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and ... in cytokine signalling and hematopoiesis. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
The omega-3 carboxylic acid (OM3-CA) is a new formulation of omega-3 fatty acids that present an enhanced bioavailability in the treatment of dyslipidemia. The increased bioavailability is explained because OM3-CA is found in a form of polyunsaturated free fatty acids as opposed to other products whose form is as ethyl...
Approved
Investigational
Matched Description: … such as alpha-tocopherol, gelatin, glycerol, sorbitol and purified water. ... acid as the most abundant species found in a proportion of 55% and 20% respectively. ... It is a complex mixture of the free fatty acids form containing eicosapentaenoic acid and docosahexaenoic …
Cetalkonium is a C16 alkyl benzalkonium chloride derivative with an amphipathic property which allows it to be used in different types of formulations. It is a quaternary ammonium salt that acts as an antiseptic against a variety of bacteria and fungi. Cetalkonium is approved by the FDA for its use...
Approved
Matched Description: … [A27143] It is a quaternary ammonium salt that acts as an antiseptic against a variety of bacteria and
Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a degree...
Approved
Matched Description: … Nabumetone was developed by Smithkline Beecham under the trade name Relafen and first received FDA approval …
Matched Categories: … Antiinflammatory and Antirheumatic Products ... Antiinflammatory and Antirheumatic Products, Non-Steroids …
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein...
Approved
Investigational
Matched Description: … pathogenesis of CML and 15-30% of ALL cases. ... ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain. ... acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Balsalazide is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease. It is sold under the name "Colazal" in the US and "Colazide" in the UK. The chemical name is (E)-5-[[-4-(2-carboxyethyl) aminocarbonyl] phenyl]azo] -2-hydroxybenzoic acid. It is usually administered as the disodium salt. Balsalazide works by deliverying mesalazine...
Approved
Investigational
Matched Description: … It is sold under the name "Colazal" in the US and "Colazide" in the UK. …
Matched Categories: … Alimentary Tract and Metabolism …
Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic...
Approved
Investigational
Matched Description: … It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription ... risk for metastases and death [A31846]. ... Apalutamide displayed good tolerability and safety profile in clinical studies. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents …
Approved
Experimental
Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.
Approved
Matched Categories: … formoterol and aclidinium bromide …
Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and...
Approved
Matched Description: … Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting ... The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients ... It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically …
Matched Categories: … Leflunomide and metabolite ... Antineoplastic and Immunomodulating Agents …
Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was...
Approved
Investigational
Matched Description: … By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune ... European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was developed by Pfizer Inc and approved by the FDA on...
Approved
Investigational
Matched Description: … [A40009] Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Amlexanox is an antiallergic drug, clinically effective for atopic diseases, especially allergic asthma and rhinitis. Amlexanox as a topical paste is a well tolerated treatment of recurrent aphthous ulcers. Recurrent aphthous ulcer (RAU) is the most prevalent oral mucosal disease in humans, estimated to affect between 5% and 50% of...
Approved
Investigational
Withdrawn
Matched Description: … Amlexanox is an antiallergic drug, clinically effective for atopic diseases, especially allergic asthma and ... aphthous ulcer (RAU) is the most prevalent oral mucosal disease in humans, estimated to affect between 5% and
Matched Categories: … Alimentary Tract and Metabolism …
Gliquidone is a sulfonylurea drug used to treat diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, and eventually increases insulin release.
Approved
Investigational
Matched Description: … + influx, and eventually increases insulin release. ... This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2 …
Matched Categories: … Alimentary Tract and Metabolism …
Teicoplanin is a glycopeptide antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their β-D-glucosamine...
Approved
Investigational
Matched Description: … antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and ... All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Idarucizumab is a humanized monoclonal antibody fragment (Fab) derived from an immunoglobulin G1 isotype molecule that binds to and inactivates the oral anticoagulant dabigatran, thereby reversing its anticoagulant effect. As a direct acting oral anticoagulant (DOAC), one of the risks associated with the use of dabigatran includes bleeding, espeically when...
Approved
Matched Description: … monoclonal antibody fragment (Fab) derived from an immunoglobulin G1 isotype molecule that binds to and ... Its use is associated with immediate, complete and sustained reversal of the anticoagulant effects of …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Sulfaphenazole is a sulfonamide antibacterial.
Approved
Matched Categories: … Sulfonamides and trimethoprim ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Ethambutol is a bacteriostatic agent indicated alongside medications such as isoniazid, rifampin, and pyrazinamide in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of Mycobacterium tuberculosis. Ethambutol was granted FDA...
Approved
Matched Description: … Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and
Matched Categories: … ethambutol and isoniazid ... rifampicin, ethambutol and isoniazid ... rifampicin, pyrazinamide, ethambutol and isoniazid …
An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.
Approved
Investigational
Matched Description: … ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and
Zytron (DMPA) is under investigation for the treatment and health services research of HIV, Lactation, Contraception, Postpartum Depression, and Immune Cells (Mucosal and Systemic). DMPA has been investigated for the prevention, treatment, and basic science of Weight and Microbiota.
Approved
Investigational
Matched Description: … , Contraception, Postpartum Depression, and Immune Cells (Mucosal and Systemic). ... DMPA has been investigated for the prevention, treatment, and basic science of Weight and Microbiota. ... Zytron (DMPA) is under investigation for the treatment and health services research of HIV, Lactation …
Belzutifan is an inhibitor of hypoxia-inducible factor 2α (HIF-2α) used in the treatment of von Hippel-Lindau (VHL) disease-associated cancers. The HIF-2α protein was first identified in the 1990s by researchers at UT Southwestern Medical Center as a key player in the growth of certain cancers. Initially considered to be undruggable,...
Approved
Investigational
Matched Description: … binding pocket was eventually discovered in the HIF-2α molecule which allowed for compounds to bind and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Displaying drugs 751 - 775 of 14415 in total